Continuous infusion of interleukin-2 in children with refractory malignancies. 1993

R C Ribeiro, and D Rill, and P K Roberson, and W L Furman, and C B Pratt, and M Brenner, and W M Crist, and C H Pui
Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101.

BACKGROUND The toxicity of interleukin-2 (IL-2) administered by continuous infusion has not been investigated in children. METHODS This study enrolled 10 boys and 7 girls with refractory malignancy. Recombinant IL-2 was infused continuously for cycles of 120 hours at doses escalating from 3 to 30 x 10(6) IU/m2 per day. RESULTS A total of 45 cycles was administered. The most common toxicities included fever, anemia, hypotension (usually responsive to fluid bolus), hyponatremia, oliguria, hypoalbuminemia, nausea, thrombocytopenia, vomiting, and weight gain. Most side effects were correlated significantly with a dosage of 18 x 10(6) IU/m2 or more per day. Respiratory distress was infrequent. Two cycles were interrupted due to severe toxicity (hypotension in one case and confusion in another), but there were no fatalities. During infusion, there was a significant nondose-related increase in serum IL-2 receptor levels. Despite this evidence of immunomodulation, no objective tumor response was noted. CONCLUSIONS Continuous infusion of IL-2 at doses up to 30 x 10(6) IU/m2 per day can be administered safely to children by this method.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008297 Male Males
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R C Ribeiro, and D Rill, and P K Roberson, and W L Furman, and C B Pratt, and M Brenner, and W M Crist, and C H Pui
December 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy,
R C Ribeiro, and D Rill, and P K Roberson, and W L Furman, and C B Pratt, and M Brenner, and W M Crist, and C H Pui
January 1989, Medical and pediatric oncology,
R C Ribeiro, and D Rill, and P K Roberson, and W L Furman, and C B Pratt, and M Brenner, and W M Crist, and C H Pui
January 1991, Pediatric nephrology (Berlin, Germany),
R C Ribeiro, and D Rill, and P K Roberson, and W L Furman, and C B Pratt, and M Brenner, and W M Crist, and C H Pui
June 1989, Cancer treatment reviews,
R C Ribeiro, and D Rill, and P K Roberson, and W L Furman, and C B Pratt, and M Brenner, and W M Crist, and C H Pui
September 1996, Intensive care medicine,
R C Ribeiro, and D Rill, and P K Roberson, and W L Furman, and C B Pratt, and M Brenner, and W M Crist, and C H Pui
June 2012, Journal of child neurology,
R C Ribeiro, and D Rill, and P K Roberson, and W L Furman, and C B Pratt, and M Brenner, and W M Crist, and C H Pui
October 1986, Gynecologic oncology,
R C Ribeiro, and D Rill, and P K Roberson, and W L Furman, and C B Pratt, and M Brenner, and W M Crist, and C H Pui
January 1998, Journal of child neurology,
R C Ribeiro, and D Rill, and P K Roberson, and W L Furman, and C B Pratt, and M Brenner, and W M Crist, and C H Pui
August 1997, Cancer biotherapy & radiopharmaceuticals,
R C Ribeiro, and D Rill, and P K Roberson, and W L Furman, and C B Pratt, and M Brenner, and W M Crist, and C H Pui
February 2009, Cancer biotherapy & radiopharmaceuticals,
Copied contents to your clipboard!